Eli Lilly (NYSE:LLY) is acquiring Imclone (NYSE:IMCL), the maker of head and neck cancer treatment drug Erbitux, for $6.5 billion or $70 a share the company announced on October 6. Imclone stock has managed to recover from an insider trading scandal in 2001, rejection from the FDA for its Erbitux product in the same year, and a corporate raid from billionaire investor Carl Icahn in 2006.

Imclone is a company dedicated to the field of oncology that investors should get to know even as it is undergoing its own transformation.

Lilly's Stable
Eli Lilly brings to the table its lineup of drugs including schizophrenia drug Zyprexa, its depression drug Cymbalta and its cancer fighter Gemzar. Lilly's top three selling drugs previously mentioned made up 45% of its $9.9 billion in revenue for the first half of 2008. Lilly, in conjunction with ICOS Corporation, is also the maker of erectile dysfunction drug Cialis, one of the company's fastest growing drugs in terms of sales from the previous year.

Imclone Second Quarter 2008
Imclone was able to increase revenue 12.75% for the first half of the year to $329 million over the same period a year ago. Merck (NYSE:MRK) and Bristol-Myers Squibb (NYSE:BMY) are the primary contributors to Imclone's revenue from royalties, licensing and milestone fees from the worldwide sales of Erbitux. While the numbers appear promising, Imclone revenue could not exceed the pace of its expenses. Higher costs related to a patent dispute with Abbott Labs (NYSE:ABT), SG&A and R&D sent expenses up 27.66% which caused operating income to drop 21.71% to $69 million. Despite the growth of expenses investors have rewarded Imclone by pushing its stock price up 51.49% this year.

Many individuals know, whether it's through personal experience or by way of friends and family, the devastating effects cancer can have on a loved one. Although forecasts by the American Cancer Society calculate the estimate for new cancer cases to rise from 12 million in 2007 to 27 million by 2050, preventative measures including regular doctor visits, limiting the use of tobacco products, regular exercise and healthy dietary choices can have a positive impact and reverse the trend.

Final Thoughts
On the day of the announcement Eli Lilly's stock traded down more than 7% intraday on news of the premium it will be paying to acquire Imclone. This continued Eli Lilly's downward trajectory over the past year. Although the Imclone will be a part of the much larger Lilly, the new combination of drugs treatments available benefits investors by diversifying marketable products of the underlying investment. Investors should consider a dollar cost averaging approach to buy into Lilly as a way to stay close to Imclone.

For more on this strategy, read Dollar-Cost Averaging Pays.

Related Articles
  1. Mutual Funds & ETFs

    What Exactly Are Arbitrage Mutual Funds?

    Learn about arbitrage funds and how this type of investment generates profits by taking advantage of price differentials between the cash and futures markets.
  2. Investing News

    Ferrari’s IPO: Ready to Roll or Poor Timing?

    Will Ferrari's shares move fast off the line only to sputter later?
  3. Stock Analysis

    5 Cheap Dividend Stocks for a Bear Market

    Here are five stocks that pay safe dividends and should be at least somewhat resilient to a bear market.
  4. Investing

    How to Win More by Losing Less in Today’s Markets

    The further you fall, the harder it is to climb back up. It’s a universal truth that is painfully apparent in the investing world.
  5. Fundamental Analysis

    Use Options Data To Predict Stock Market Direction

    Options market trading data can provide important insights about the direction of stocks and the overall market. Here’s how to track it.
  6. Stock Analysis

    2 Oil Stocks to Buy Right Now (PSX,TSO)

    Can these two oil stocks buck the trend?
  7. Investing News

    What Alcoa’s (AA) Breakup Means for Investors

    Alcoa plans to split into two companies. Is this a bullish catalyst for investors?
  8. Stock Analysis

    Top 3 Stocks for the Coming Holiday Season

    If you want to buck the bear market trend by going long on consumer stocks, these three might be your best bets.
  9. Investing News

    Could a Rate Hike Send Stocks Higher?

    A rate hike would certainly alter the investment scene, but would it be for the better or worse?
  10. Investing News

    Corporate Bonds or Stocks: Which is Better Now?

    With market volatility high, you may think it is time to run for corporate bonds instead of stocks. Before you do take a deeper look into which is better.
  1. How do dividends affect retained earnings?

    When a company issues a cash dividend to its shareholders, the retained earnings listed on the balance sheet are reduced ... Read Full Answer >>
  2. What is the difference between called-up share capital and paid-up share capital?

    The difference between called-up share capital and paid-up share capital is investors have already paid in full for paid-up ... Read Full Answer >>
  3. Why would a corporation issue convertible bonds?

    A convertible bond represents a hybrid security that has bond and equity features; this type of bond allows the conversion ... Read Full Answer >>
  4. How does additional paid in capital affect retained earnings?

    Both additional paid-in capital and retained earnings are entries under the shareholders' equity section of a company's balance ... Read Full Answer >>
  5. What types of capital are not considered share capital?

    The money a business uses to fund operations or growth is called capital, and there are a number of capital sources available. ... Read Full Answer >>
  6. What is the difference between issued share capital and subscribed share capital?

    The difference between subscribed share capital and issued share capital is the former relates to the amount of stock for ... Read Full Answer >>

You May Also Like

Trading Center
You are using adblocking software

Want access to all of Investopedia? Add us to your “whitelist”
so you'll never miss a feature!